Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer

Patients with platinum-resistant ovarian cancer (PROC) have limited therapeutic options and poor survival. There is a need for the development of newer therapies. Sodium valproic acid (VPA) is a short-chain fatty acid histone deacetylase (HDAC) inhibitor with antitumor activity in preclinical models...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakka, Thejeswar, Goenka, Luxitaa, Dubashi, Biswajit, Kayal, Smita, Mathaiyan, Jayanthi, Barathi, Deepak, Krishnamoorthy, Narendran, Thumaty, Divya Bala, Dahagama, Sindhu, Ganesan, Prasanth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522437/
https://www.ncbi.nlm.nih.gov/pubmed/36175588
http://dx.doi.org/10.1007/s12032-022-01833-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522437/
https://www.ncbi.nlm.nih.gov/pubmed/36175588
http://dx.doi.org/10.1007/s12032-022-01833-6

Ejemplares similares